In the BioHarmony Drug Report Database

"Preview" Icon

Moxetumomab pasudotox

Lumoxiti (moxetumomab pasudotox) is an antibody pharmaceutical. Moxetumomab pasudotox was first approved as Lumoxiti on 2018-09-13. It is used to treat hairy cell leukemia in the USA. The pharmaceutical is active against B-cell receptor CD22.

 

Trade Name

 

Lumoxiti
 

Common Name

 

moxetumomab pasudotox
 

ChEMBL ID

 

CHEMBL1743043
 

Indication

 

hairy cell leukemia
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Moxetumomab pasudotox structure rendering